The immunogenicity of mutp53 has been confirmed by a p53-specific screening assay showing that mutp53 neoantigens can be recognized by tumor-infiltrating lymphocytes in patients with epithelial cancers (Malekzadeh et al., 2019). Here, TP53 is linked to neoplasm.